A four-week, multicenter, double-blinded, randomized, active- and placebo controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients

​In collaboration with research partners at Ruprecht-Karls-University Heidelberg in Germany, this study evaluates the efficacy of cannabidiol (ECP012A) in alleviating the positive, negative and general symptoms of schizophrenia compared to olanzapine and placebo.

Cannabidiol is a natural counterpart of the psychoactive component of marijuana, Δ9-tetrahydrocannabinol. While cannabidiol does not activate cannabinoid receptors and has no psychotomimetic or addictive properties, it indirectly affects endogenous cannabinoid signaling by impairing the degradation of anandamide and by modulating the activity of CB1-type cannabinoid receptors in the brain.

This study tests the efficacy and safety of cannabidiol (ECP012A), a potential enhancer of endocannabinoid action, in comparison to placebo and olanzapine in patients suffering from acute schizophrenia who are within the first three years of illness. Furthermore, the impact of cannabidiol (ECP012A) on metabolic functioning is compared to that of placebo and olanzapine and the incidence of extrapyramidal unwanted effects following cannabidiol (ECP012A) treatment is quantified compared to placebo and olanzapine.

The study is funded by the Seventh Framework Programme under the European Union and it is performed in collaboration with partners across Germany as well as in Bucharest, Romania. The study is currently set to conclude in 2018 and inclusion has been paused.